{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:25:03Z","timestamp":1793834703256,"version":"4.6.1"},"reference-count":86,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Anaplastic large cell lymphoma (ALCL) is a rare form of mature T-cell non-Hodgkin lymphoma. In pediatric patients, most cases are anaplastic lymphoma kinase (ALK) positive. Despite intensive multiagent chemotherapy regimens, treatment failure rates remain at 25% to 30%. Recent advancements in targeted therapies, notably ALK inhibitors and the anti-CD30 antibody-drug conjugate brentuximab vedotin have demonstrated substantial activity in relapsed and refractory settings. Molecular detection of minimal disseminated disease (MDD) and minimal residual disease (MRD) offers improved prognostic stratification. For patients with relapsed or refractory disease, targeted therapies have increased treatment options, but more work needs to be done to define optimal treatment regimens, duration, and need for hematopoietic stem cell transplantation in this group. Immune therapies such as checkpoint inhibitors or chimeric antigen receptor T-cell therapy provide additional therapeutic options. Incorporating targeted therapies and MDD\/MRD assessments into clinical trials could significantly improve outcomes for pediatric and adolescent patients with ALCL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015935","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T20:49:30Z","timestamp":1753130970000},"page":"4870-4880","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Advances and updates in pediatric anaplastic large cell lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6036-3127","authenticated-orcid":false,"given":"Lianna J.","family":"Marks","sequence":"first","affiliation":[{"name":"1Division of Pediatric Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5367-3477","authenticated-orcid":false,"given":"Eric","family":"Lowe","sequence":"additional","affiliation":[{"name":"2Department of Pediatric Hematology\/Oncology, Children\u2019s Hospital of the King\u2019s Daughters, Norfolk, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0892-7727","authenticated-orcid":false,"given":"Kala","family":"Kamdar","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"12","key":"2025101410163817100_bib1","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"key":"2025101410163817100_bib2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017","edition":"4th ed"},{"issue":"5151","key":"2025101410163817100_bib3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"issue":"19","key":"2025101410163817100_bib4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM199605093341906","article-title":"Non-Hodgkin's lymphoma in childhood","volume":"334","author":"Sandlund","year":"1996","journal-title":"N Engl J Med"},{"issue":"5","key":"2025101410163817100_bib5","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1200\/JCO.1994.12.5.899","article-title":"Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies","volume":"12","author":"Reiter","year":"1994","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025101410163817100_bib6","first-page":"3591","article-title":"CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology","volume":"92","author":"Brugi\u00e8res","year":"1998","journal-title":"Blood"},{"issue":"12","key":"2025101410163817100_bib7","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.V97.12.3699","article-title":"Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-M\u00fcnster Group Trial NHL-BFM 90","volume":"97","author":"Seidemann","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2025101410163817100_bib8","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1046\/j.1365-2141.2002.03482.x","article-title":"Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on the United Kingdom Children's Cancer Study Group chemotherapy regimens","volume":"117","author":"Williams","year":"2002","journal-title":"Br J Haematol"},{"issue":"10","key":"2025101410163817100_bib9","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/cncr.21438","article-title":"Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol","volume":"104","author":"Rosolen","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"2025101410163817100_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.2005.11.075","article-title":"Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial","volume":"23","author":"Laver","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025101410163817100_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pbc.21817","article-title":"Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941","volume":"52","author":"Lowe","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2025101410163817100_bib12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","article-title":"Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group","volume":"27","author":"Brugi\u00e8res","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025101410163817100_bib13","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2010.28.5999","article-title":"Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial","volume":"28","author":"Le Deley","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025101410163817100_bib14","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/pbc.25187","article-title":"Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group","volume":"61","author":"Alexander","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"26","key":"2025101410163817100_bib15","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.2020009806","article-title":"Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ALCL: results of COG trial ANHL12P1","volume":"137","author":"Lowe","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2025101410163817100_bib16","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1200\/JCO.22.00272","article-title":"Crizotinib in combination with chemotherapy for pediatric patients with ALK+ anaplastic large-cell lymphoma: the results of Children's Oncology Group trial ANHL12P1","volume":"41","author":"Lowe","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025101410163817100_bib17","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/pbc.24125","article-title":"Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood","volume":"59","author":"Pillon","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2025101410163817100_bib18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2007-02-066852","article-title":"Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma","volume":"110","author":"Damm-Welk","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2025101410163817100_bib19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/leu.2012.205","article-title":"Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis","volume":"27","author":"Mussolin","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2025101410163817100_bib20","doi-asserted-by":"crossref","first-page":"e28982","DOI":"10.1002\/pbc.28982","article-title":"Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?","volume":"68","author":"Rigaud","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2025101410163817100_bib21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1200\/JCO.1994.12.5.895","article-title":"Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma","volume":"12","author":"Sandlund","year":"1994","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025101410163817100_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.12728","article-title":"Clinical analysis and prognostic significance of haemophagocytic lymphohistiocytosis-associated anaplastic large cell lymphoma in children","volume":"165","author":"Pasqualini","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"2025101410163817100_bib23","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non-Hodgkins lymphomas - dissimilarities from lymphomas in adults","volume":"7","author":"Murphy","year":"1980","journal-title":"Semin Oncol"},{"issue":"18","key":"2025101410163817100_bib24","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","article-title":"Revised international pediatric non-Hodgkin lymphoma staging system","volume":"33","author":"Rosolen","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025101410163817100_bib30","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4143\/crt.2024.104","article-title":"Stratified treatment in pediatric anaplastic large cell lymphoma: result of a prospective open-label multiple-institution study","volume":"56","author":"Chen","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"3","key":"2025101410163817100_bib38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"2025101410163817100_bib25","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.3390\/cancers12102747","article-title":"Prognostic factors in childhood anaplastic large cell lymphoma: long term results of the international ALCL99 trial","volume":"12","author":"Mussolin","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"21","key":"2025101410163817100_bib26","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1182\/blood-2010-12-324012","article-title":"Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma","volume":"117","author":"Attarbaschi","year":"2011","journal-title":"Blood"},{"issue":"28","key":"2025101410163817100_bib27","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children's Oncology Group Study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025101410163817100_bib28","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2025101410163817100_bib29","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"issue":"12","key":"2025101410163817100_bib31","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2025101410163817100_bib32","first-page":"2697","article-title":"ALK+ lymphoma: clinico-pathological findings and outcome","volume":"93","author":"Falini","year":"1999","journal-title":"Blood"},{"issue":"11","key":"2025101410163817100_bib33","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","article-title":"Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma","volume":"93","author":"Gascoyne","year":"1999","journal-title":"Blood"},{"issue":"32","key":"2025101410163817100_bib34","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J Clin Oncol"},{"issue":"18","key":"2025101410163817100_bib35","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2025101410163817100_bib36","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"28","key":"2025101410163817100_bib37","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10168","key":"2025101410163817100_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"2025101410163817100_bib40","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/S2352-3026(24)00171-6","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study","volume":"11","author":"Herrera","year":"2024","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025101410163817100_bib41","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood-2007-07-100958","article-title":"Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study","volume":"111","author":"Le Deley","year":"2008","journal-title":"Blood"},{"issue":"35","key":"2025101410163817100_bib42","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1200\/JCO.2011.36.5411","article-title":"Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study","volume":"29","author":"Lamant","year":"2011","journal-title":"J Clin Oncol"},{"issue":"16","key":"2025101410163817100_bib43","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2009-11-251892","article-title":"Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk","volume":"115","author":"Ait-Tahar","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2025101410163817100_bib44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41375-024-02468-4","article-title":"Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma","volume":"39","author":"Shaw","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"2025101410163817100_bib45","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/bjh.19308","article-title":"Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): a population-based paediatric study of the NHL-BFM study group","volume":"204","author":"Luedersen","year":"2024","journal-title":"Br J Haematol"},{"issue":"7","key":"2025101410163817100_bib46","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/cancers14071703","article-title":"Quantification of minimal disease by digital PCR in ALK-positive anaplastic large cell lymphoma: a step towards risk stratification in international trials?","volume":"14","author":"Damm-Welk","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"22","key":"2025101410163817100_bib47","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2011.34.8417","article-title":"Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study","volume":"29","author":"Woessmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025101410163817100_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1008352726155","article-title":"Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology","volume":"11","author":"Brugi\u00e8res","year":"2000","journal-title":"Ann Oncol"},{"issue":"1","key":"2025101410163817100_bib49","doi-asserted-by":"crossref","first-page":"e31397","DOI":"10.1002\/pbc.31397","article-title":"Outcome of childhood ALK-positive anaplastic large cell lymphoma relapses: real-life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French children","volume":"72","author":"Pereira","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"34","key":"2025101410163817100_bib50","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1200\/JCO.20.00157","article-title":"Stem cell transplantation and vinblastine monotherapy for relapsed pediatric anaplastic large cell lymphoma: results of the international, prospective ALCL-relapse trial","volume":"38","author":"Kn\u00f6rr","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025101410163817100_bib54","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"issue":"12","key":"2025101410163817100_bib55","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","article-title":"Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study","volume":"22","author":"Fischer","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025101410163817100_bib52","doi-asserted-by":"crossref","first-page":"112984","DOI":"10.1016\/j.ejca.2023.112984","article-title":"Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcS\u00e9-crizotinib trial","volume":"191","author":"Brugi\u00e8res","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"2025101410163817100_bib53","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1182\/bloodadvances.2022007538","article-title":"A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed\/refractory ALK+ lymphomas","volume":"7","author":"Rindone","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2025101410163817100_bib62","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3324\/haematol.2022.281896","article-title":"Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma","volume":"108","author":"Kn\u00f6rr","year":"2023","journal-title":"Haematologica"},{"issue":"suppl 16","key":"2025101410163817100_bib56","doi-asserted-by":"crossref","first-page":"10017","DOI":"10.1200\/JCO.2024.42.16_suppl.10017","article-title":"Brigatinib monotherapy in children with R\/R ALK+ ALCL, IMT, or other solid tumors: results from the BrigaPED (ITCC-098) phase 1 study","volume":"42","author":"Rigaud","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025101410163817100_bib51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/cancers10040099","article-title":"Treatment options for paediatric anaplastic large cell lymphoma (ALCL): current standard and beyond","volume":"10","author":"Prokoph","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025101410163817100_bib57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1511045","article-title":"Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib","volume":"374","author":"Gambacorti-Passerini","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2025101410163817100_bib58","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2024014745","article-title":"Pediatric relapsed\/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era","volume":"9","author":"Marks","year":"2025","journal-title":"Blood Adv"},{"key":"2025101410163817100_bib59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2025101410163817100_bib60","doi-asserted-by":"crossref","first-page":"101444","DOI":"10.1016\/j.beha.2023.101444","article-title":"Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents","volume":"36","author":"Rigaud","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"issue":"30","key":"2025101410163817100_bib61","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1200\/JCO.2008.20.1764","article-title":"Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology","volume":"27","author":"Brugi\u00e8res","year":"2009","journal-title":"J Clin Oncol"},{"issue":"13","key":"2025101410163817100_bib63","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2025101410163817100_bib64","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00277-016-2764-1","article-title":"Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety","volume":"95","author":"Chan","year":"2016","journal-title":"Ann Hematol"},{"issue":"8","key":"2025101410163817100_bib65","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7326\/L16-0037","article-title":"Nivolumab for refractory anaplastic large cell lymphoma: a case report","volume":"165","author":"Hebart","year":"2016","journal-title":"Ann Intern Med"},{"issue":"4","key":"2025101410163817100_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26902","article-title":"Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma","volume":"65","author":"Rigaud","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2025101410163817100_bib67","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"issue":"1","key":"2025101410163817100_bib68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-020-0274-9","article-title":"Anti-CD30 chimeric antigen receptor T cell therapy for relapsed\/refractory CD30+ lymphoma patients","volume":"10","author":"Wang","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025101410163817100_bib69","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","article-title":"Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial","volume":"8","author":"Brudno","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2025101410163817100_bib70","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2352-3026(24)00064-4","article-title":"Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study","volume":"11","author":"Grover","year":"2024","journal-title":"Lancet Haematol"},{"issue":"2","key":"2025101410163817100_bib71","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2006.06004.x","article-title":"Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-M\u00fcnster Group report","volume":"133","author":"Woessmann","year":"2006","journal-title":"Br J Haematol"},{"issue":"2","key":"2025101410163817100_bib72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2025101410163817100_bib73","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjh.13167","article-title":"Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan","volume":"168","author":"Fukano","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2025101410163817100_bib74","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/bmt.2015.57","article-title":"Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC","volume":"50","author":"Strullu","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"2025101410163817100_bib75","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025101410163817100_bib76","doi-asserted-by":"crossref","first-page":"e13210","DOI":"10.1111\/petr.13210","article-title":"Allogeneic hematopoietic cell transplant following crizotinib monotherapy for relapsed\/refractory anaplastic large cell lymphoma","volume":"22","author":"John","year":"2018","journal-title":"Pediatr Transplant"},{"issue":"6","key":"2025101410163817100_bib77","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12185-019-02748-1","article-title":"Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma","volume":"110","author":"Fukano","year":"2019","journal-title":"Int J Hematol"},{"issue":"10","key":"2025101410163817100_bib78","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1002\/pbc.24591","article-title":"Central nervous system involvement in anaplastic large cell lymphoma in childhood: results from a multicentre European and Japanese study","volume":"60","author":"Williams","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2025101410163817100_bib79","doi-asserted-by":"crossref","first-page":"e27003","DOI":"10.1002\/pbc.27003","article-title":"CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: a case series","volume":"65","author":"Ruf","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2025101410163817100_bib80","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.3324\/haematol.2021.280081","article-title":"Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement","volume":"107","author":"Rigaud","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"2025101410163817100_bib81","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/ced.14777","article-title":"Primary cutaneous anaplastic large-cell lymphoma: a review of the SEER database from 2005 to 2016","volume":"46","author":"Sarfraz","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"16","key":"2025101410163817100_bib82","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.3390\/cancers15164098","article-title":"Primary cutaneous anaplastic large cell lymphoma-a review of clinical, morphological, immunohistochemical, and molecular features","volume":"15","author":"Ortiz-Hidalgo","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025101410163817100_bib83","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.2012.065664","article-title":"ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study","volume":"98","author":"Oschlies","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"2025101410163817100_bib84","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2025101410163817100_bib85","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/bloodadvances.2020001581","article-title":"ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project","volume":"5","author":"Shustov","year":"2021","journal-title":"Blood Adv"},{"issue":"702","key":"2025101410163817100_bib86","doi-asserted-by":"crossref","first-page":"eabo3826","DOI":"10.1126\/scitranslmed.abo3826","article-title":"Targeting CCR7-PI3K\u03b3 overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma","volume":"15","author":"Mastini","year":"2023","journal-title":"Sci Transl Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4870\/2414124\/blooda_adv-2025-015935-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4870\/2414124\/blooda_adv-2025-015935-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:34:52Z","timestamp":1760452492000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/19\/4870\/546291\/Advances-and-updates-in-pediatric-anaplastic-large"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":86,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015935","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,14]]},"published":{"date-parts":[[2025,9,26]]}}}